PFS
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Huaiyuan Xu, Jinxin Hu, Yun Zhang, Aihua Zhuang, Yingchun Zhang, Jibin Li, Hao Wu, Guohui Song, Chuanquan Deng, Hongmin Chen, Weiqing Chen, Chuangzhong Deng, Anqi Wang, Huixiong Feng, Jinchang Lu, Qinglian Tang, Xiaojun Zhu, Jin Wang
Clin Cancer Res 32(11) 2198-2205
PURPOSE: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT). PATIENTS AND METHODS: In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. RESULTS: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01-0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05). CONCLUSIONS: PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs. See related commentary by Dossa et al., p. 2127.
1 个 Figure · 1 个 KM 面板
Figure 2. PFS and subgroup analysis. A, Kaplan–Meier estimates of PFS. Disease progression was identified by the investigators and included imaging-based progression according to RECIST 1.1 and clinical progression. Tick marks indicate censored data. B, Forest plot of PFS in prespecified subgroups. Disease progression was identified by the investigators and included imaging-based progression according to RECIST 1.1 and clinical progression. NE, not evaluated.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。